近期，北京市西城区市场监管局月坛街道市场监管所对药品零售（连锁）药店开展处方药销售检查行动。检查中，执法人员要求 药品经营单位严格落实处方药销售管理规定，做好处方审核与留存工作，定期核对处方信息与销售记录，严禁处方药开架自选陈 列销售。本报记者董芳忠摄影报道 （来源：中国消费者报） ...

（编辑 丛可心） 证券日报网讯 12月17日，健之佳在互动平台回答投资者提问时表示，公司以顾客需求为核心，聚焦主 业，长期专注于差异化定位的药品零售、便利零售行业，持续强化核心竞争力。面对政策影响、医药消 费低迷、行业短期压力和中期转型挑战，公司迅速调整短期经营策略，坚决转型，聚焦存量门店效率以 争取市场份额。非常感谢投资者对公司的关注以及提出的转型建议，一方面对跨行业、跨界进入不熟 悉、公司尚未具备优势的竞争性领域，公司持开放但审慎的态度评估风险及自身能力潜力，另一方面， 坚决推进转型工作，以提升店效、人效。 ...

齐鲁晚报·齐鲁壹点 李梓博 日前，"2025淄博企业100强""2025淄博制造业企业100强""2025淄博服务业企业30强"名单公布。 据悉，为引导淄博企业加快做大做强做优，打造更多具有国内国际一流竞争力的龙头骨干企业，经企业 自愿申报、区县推荐、市级审核、部门征询意见、社会公示等程序，最终确定上述名单。 两年前，山东信宏仁医药迎来品牌升级，由单一药品零售企业升级为健康产业集团。与此同时，山东神 奇医药产业园建成投用，该项目总建筑面积66500平方米，总投资约3亿元，主要建设内容包括仓储中 心、研发中心、质检中心、综合服务区及生产生活配套设施等。 其中，山东信宏仁医药有限公司入围"2025淄博企业100强""2025淄博服务业企业30强"名单。 未来，山东信宏仁医药将继续坚持"诚信、精进、利他、客户至上"的核心价值观，秉承"帮助患者解除 病痛、帮助员工成长、奉献社会"的企业精神，不断提升企业核心竞争力，心怀感恩和恭敬之心，不忘 初衷，为人民群众提供全方位全生命周期的健康管理服务，服务百姓健康100年，为健康中国建设贡献 力量。 这是这家区域药品零售龙头企业首次入围该榜单，在"2025淄博企业100强"名单 ...

Group 1: Company Overview - Long Fung Group Holdings Limited has submitted its main board listing application to the Hong Kong Stock Exchange, with DBS Asia Capital as the sole sponsor [1] - The company holds a 5.2% market share, making it the largest pharmaceutical retailer in Hong Kong, and also the largest cosmetic retailer by average SKU per store [2][3] Group 2: Business Operations - Long Fung operates 29 retail stores in Hong Kong and various online channels, including its official website and major e-commerce platforms [2] - The company has a diverse product matrix covering 11 categories, including traditional Chinese medicine, Western medicine, health supplements, and cosmetics, with over 46,000 SKUs sold during the reporting period [2] Group 3: Financial Performance - Revenue has shown significant growth from HKD 1.094 billion in FY2023 to HKD 2.460 billion in FY2025, with a gross margin improvement from 24.9% to 31.6% during the same period [3][4] - The company transitioned from a loss of HKD 25.2 million in FY2023 to a profit of HKD 218 million in FY2025, with a tax-pre profit of HKD 59.9 million in Q1 FY2026, reflecting over 100% year-on-year growth [4][5] Group 4: Market Trends - The Hong Kong pharmaceutical market is projected to grow from approximately HKD 57.88 billion in 2020 to HKD 85.08 billion in 2024, with a compound annual growth rate (CAGR) of 10.1% [7] - Key structural trends driving market growth include the integration of traditional Chinese and Western medicine, and the rising demand for personalized healthcare solutions [8] Group 5: Competitive Landscape - The market is highly fragmented, with the top five retailers holding only 14.6% of the market share, indicating ongoing competitive challenges for Long Fung [8] - Rising operational costs, particularly in labor and warehouse rental, are expected to continue impacting profitability [9] Group 6: Strategic Outlook - The company aims to leverage capital market opportunities to strengthen its market position and operational efficiency while exploring new growth avenues [11] - Long Fung's financial performance reflects a complex interplay of growth potential and financial risks, necessitating close monitoring of its liquidity and equity structure [11]

Core Viewpoint - Long Fung Group has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, positioning itself as the largest pharmaceutical retailer in Hong Kong with a market share of 5.2% and the largest beauty retail operator by average SKU per store, reflecting its deep understanding of consumer needs and strategic positioning over the past 30 years [1][2]. Company Overview - Long Fung Group operates a chain of retail drugstores under the "Long Fung" brand, with 29 physical stores and multiple online channels, achieving a market-leading position in Hong Kong's pharmaceutical retail sector [2]. - The company has a diverse product matrix covering 11 categories, including traditional Chinese medicine, Western medicine, health supplements, and beauty products, with over 46,000 SKUs sold during the reporting period [2]. Financial Performance - Revenue has shown significant growth from HKD 1.094 billion in the 2023 fiscal year to HKD 2.460 billion in the 2025 fiscal year, with a notable improvement in gross margin from 24.9% to 31.6% during the same period [3][4]. - The company transitioned from a loss of HKD 25.2 million in the 2023 fiscal year to a profit of HKD 218 million in the 2025 fiscal year, with a tax-pre profit of HKD 59.9 million in the first quarter of the 2026 fiscal year, indicating a remarkable turnaround [4]. Market Dynamics - The Hong Kong pharmaceutical market is projected to grow from approximately HKD 57.88 billion in 2020 to HKD 85.08 billion by 2024, with a compound annual growth rate (CAGR) of 10.1% [7]. - Key structural trends driving market growth include the integration of traditional Chinese and Western medicine and the rising demand for personalized healthcare solutions among consumers [8]. Competitive Landscape - The market is highly fragmented, with the top five retailers holding only 14.6% of the market share, indicating ongoing competitive challenges for Long Fung Group despite its leading position [8]. - Rising operational costs, particularly in labor and warehouse rental, are expected to continue impacting profitability, with average monthly salaries in the retail sector increasing from HKD 19,353.5 in 2020 to HKD 21,471.0 in 2024 [9]. Strategic Outlook - As Long Fung Group approaches its IPO, the focus will be on leveraging capital market opportunities to strengthen its market position and operational efficiency while exploring new growth avenues for sustainable expansion [11]. - The company faces a complex landscape of growth potential intertwined with financial risks, necessitating careful management of its liquidity structure and equity base to ensure long-term stability [11].

Core Insights - The National Health Commission reported that 17 provinces in China are experiencing high levels of influenza activity, with a positive rate of 51% for flu virus tests among patients with flu-like symptoms [1] - In response to the urgent need for respiratory health protection during the flu season, Kunming Pharmaceutical Group and Yixintang Pharmaceutical initiated the "Clear Lung Action" campaign to promote public awareness of respiratory health and scientific prevention methods [1] Group 1 - The "Clear Lung Action" event featured interactive activities where citizens learned about health, received themed gifts, and engaged in various functional areas, including a large lung-clearing device that attracted many participants [2] - Medical experts provided insights on the relationship between influenza and lung health, symptom recognition, and scientific prevention methods, while free consultations were offered to the public [2] - Participants could measure their lung capacity and function through the "One Breath Lung Challenge," and learn practical lung health maintenance methods through exercises that combine traditional and modern techniques [2] Group 2 - The core concept of the "Clear Lung Action" is based on Kunming Pharmaceutical Group's flagship product, "Kun Traditional Chinese Medicine Clear Lung Phlegm Pill," which has historical roots dating back to the Song Dynasty and is known for its efficacy in clearing lungs and relieving cough [3] - Kunming Pharmaceutical Group's subsidiary, Kun Traditional Chinese Medicine, is recognized as the "oldest pharmaceutical company" by Guinness World Records and has been awarded the "Chinese Time-Honored Brand" honor [3] - Yixintang, a leading retail pharmacy chain in China, operates over 11,230 stores and serves approximately 210 million customers annually, enhancing the reach of health education initiatives [3] Group 3 - The collaboration between leading pharmaceutical companies and large retail pharmacy chains is advancing health education from one-way communication to interactive engagement, emphasizing preventive health measures in the context of the "Healthy China" strategy [4] - The "Clear Lung Action" effectively integrates traditional Chinese medicine's preventive wisdom with contemporary health management practices to safeguard public respiratory health [4]

Core Viewpoint - The medical ETF (159828) has seen a net inflow for five consecutive days, driven by the advancements in the small nucleic acid sector, particularly with Arrowhead Pharmaceuticals making significant strides in chronic disease treatment and CNS (central nervous system) breakthroughs [1]. Group 1: Company Developments - Arrowhead Pharmaceuticals' market capitalization increased by $1.66 billion last week, indicating strong investor confidence [1]. - The company's first small nucleic acid product, Plozasiran, is set to receive FDA approval on November 18, 2025, marking a pivotal moment in its commercialization journey [1]. - Arrowhead is advancing its pipeline products towards larger patient markets in chronic diseases and CNS, showcasing its growth potential [1]. Group 2: Industry Insights - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the pharmaceutical and healthcare sectors from the Shanghai and Shenzhen markets [1]. - The index primarily covers sectors such as medical devices, medical services, and medical R&D outsourcing, reflecting the overall performance of related listed companies [1]. - The constituent stocks of the index tend to be small to mid-cap, characterized by high growth potential and volatility [1].

Core Viewpoint - The article discusses the announcement by the State Administration for Market Regulation (SAMR) regarding the publication of typical cases of operator concentration, aimed at enhancing compliance and transparency in mergers and acquisitions [1] Group 1: Case Summaries - Case 1: Hangzhou State Capital Investment Operation Co., Ltd. acquired shares of Zhejiang Yingde Holding Group Co., Ltd. The review focused on horizontal concentration, with a combined market share exceeding 15% in the domestic atmospheric gas supply market, leading to unconditional approval [2][3] - Case 2: Gaoji Pharmaceutical Co., Ltd. acquired shares of Tianji Pharmacy Chain Co., Ltd. and three other companies. The review focused on both horizontal and vertical concentration, with a combined market share exceeding 25% in the pharmaceutical retail market in Xiangyang, resulting in unconditional approval [8][9] - Case 3: Ouyie Chain Gold Recycling Resources Co., Ltd. acquired shares of Hebei Grey En New Materials Co., Ltd. The review focused on horizontal and vertical concentration, with a combined market share exceeding 15% in the recycled steel raw materials and crude steel markets, leading to unconditional approval [21][22] Group 2: Market Analysis - In the atmospheric gas supply market, the combined market share of Hangzhou State Capital and Zhejiang Yingde was calculated based on bidding data, showing a market share of 25-30% based on production capacity and 30-35% based on project numbers, indicating a moderate level of concentration [5][6] - In the pharmaceutical wholesale market, both the acquirer and the target had a market share of 0-5%, indicating no market control post-merger. In the online pharmaceutical retail market, the combined share was 10-15%, also indicating no market control [13][14] - In the recycled steel raw materials and crude steel markets, the combined market share was 15-20%, with HHI indices below 1000, indicating low market concentration and no significant change in market structure post-merger [24][25] Group 3: Competitive Dynamics - The competitive analysis in the atmospheric gas supply market indicated that both companies faced effective competition from other suppliers, with a significant number of projects lost to competitors, ensuring no anti-competitive effects post-merger [6][7] - In the pharmaceutical retail market, the analysis showed that the acquirer did not have significant control over the market, with low entry barriers and the presence of new entrants, ensuring competitive dynamics remained intact [17][19] - In the recycled steel market, the analysis concluded that the concentration would not lead to anti-competitive effects due to the low market shares and the presence of numerous competitors, ensuring effective competition [26]

Core Insights - The article highlights a significant inflow of 12 million units into the medical ETF (159865), indicating strong investor interest in medical assets [1] - Beijing has issued measures to promote the high-quality development of the medical device industry, focusing on various aspects such as clinical research support, application promotion, and international expansion [1] Industry Summary - The new policies aim to provide robust support for innovative medical device companies, addressing previous barriers to hospital access for new products and fostering a positive cycle between research and market [1] - The measures include financial support for qualifying innovative device enterprises, which is expected to enhance the innovation and development of medical consumables [1] - Policies related to international expansion are designed to reduce the cost burden of overseas registration for companies, particularly benefiting those seeking new market opportunities amid domestic procurement pressures [1] Company Summary - The medical ETF (159828) tracks the CSI Medical Index (399989), which selects listed companies in the pharmaceutical and healthcare sectors from the Shanghai and Shenzhen markets [1] - The index primarily covers areas such as medical devices, medical services, and medical research outsourcing, reflecting the overall performance of related listed companies [1] - The constituent stocks of the index tend to be small to mid-cap companies, characterized by high growth potential and volatility [1]

Core Viewpoint - Long Fung Group, a leading pharmacy chain in Hong Kong, has submitted a listing application to the Hong Kong Stock Exchange, with the exclusive sponsor being DBS Bank [1] Company Overview - Long Fung Group is the largest retail pharmacy in Hong Kong by retail sales, holding a market share of 5.2%, and is the second-largest retailer of health, medical, and beauty products with a market share of approximately 5.8% [1] - The company operates 29 physical retail stores in Hong Kong, with a total available floor area exceeding 123,000 square feet [1] - Long Fung's mobile application has over 200,000 members as of last November [1] Financial Performance - For the fiscal year ending March 2025, Long Fung reported a profit of HKD 170 million, a year-on-year increase of 17.92%, with revenues of HKD 2.46 billion, up 21.76% [1] - In the first quarter of the fiscal year 2026, ending June 30, the company achieved a profit of HKD 47.76 million, a year-on-year increase of over 131%, with revenues of HKD 697 million, a growth of 42.48%, primarily driven by same-store sales growth and contributions from new stores [1] Expansion Plans - The funds raised from the listing will be primarily used to expand and enhance the store and online sales network, as well as for recruitment and training, including plans to open 11 new stores [1]